In-Vivo Imaging Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global In-Vivo Imaging Market Trends and Insights

Expansion of Biopharma R&D Pipelines and Preclinical Study Complexity

Biopharma research activity remained resilient through 2025, and global clinical and preclinical pipeline volumes grew at high-single-digit annual rates from 2020. The in-vivo imaging market gains from this activity because oncology, gene therapy, and cell therapy programs need several preclinical endpoints. Imaging supports pharmacokinetics, biodistribution, and repeated disease monitoring within the same animal cohort. IQVIA reported 79 novel active substances launched globally in 2025 and expects an annual average of 70-80 through 2030. China’s larger pipeline contribution is also increasing demand for preclinical imaging capacity in Asian contract research organizations. More complex programs can require more imaging sessions per candidate, which supports demand even when pipeline volumes vary.

Shift Toward Non-Invasive Longitudinal Imaging

Non-invasive longitudinal imaging aligns with the 3Rs principles reflected in European animal-research rules and the U.S. Animal Welfare Act. The in-vivo imaging market, therefore, benefits from methods that allow repeated, minimally stressful imaging in the same animal. Optical bioluminescence, micro-MRI, and photoacoustic systems can support these repeated assessments. A 2025 peer-reviewed review identified fluorescence and bioluminescence as widely used longitudinal tools because of their ease of use, accessible instrumentation, and range of applications.^{[1]“Validation of an Automated AI-Based Micro-CT Organ Segmentation Workflow Against Expert Annotations and Its Impact on Fluorescence Quantification,”} Longitudinal designs can reduce animal numbers per study while increasing the number of sessions for each surviving animal. This pattern can protect probe and consumable demand even as study cohorts become smaller.

Adoption of Multimodal Hybrid Imaging

Hybrid systems such as PET/SPECT-CT, PET/MRI, and optical-ultrasound combinations are moving into broader use at contract research facilities. A 2025 multi-site study showed that a multimodal cradle inlay could co-register BLI, PET, micro-CT, and MRI in a metastatic colorectal cancer mouse model. The workflow brought tumor distribution, metabolic activity, inflammation, and margin assessment into one study design. Such datasets can give sponsors anatomical, functional, and molecular evidence at the same time. Bruker commissioned a BioSpec 18 Tesla preclinical MRI at the Champalimaud Foundation in May 2026, which the company described as the highest-field horizontal-bore preclinical MRI. Higher system performance and AI-supported analysis may reduce the operational barrier that previously limited multimodal imaging to specialized sites.

Rising Demand for Quantitative Translational Biomarkers

Drug sponsors need measurable evidence that can connect preclinical findings with clinical development decisions. The in-vivo imaging market supports this need through imaging biomarkers that track biological activity over time. Quantitative biomarkers can provide pharmacodynamic endpoints for studies that need more than structural images. The FDA and European Medicines Agency's interest in qualified imaging biomarkers gives these methods a stronger development role. Biomarker-led imaging can also help sponsors compare candidate therapies using repeatable measures. This demand favors platforms that combine validated acquisition methods with consistent quantitative analysis.

High Capital, Maintenance, and Qualification Costs

Capital cost remains a major barrier to adoption outside North America and Europe. A multimodal suite that combines PET/SPECT, micro-MRI, and optical imaging can require multi-million-dollar investment before qualification activities. Installation, operational, and performance qualification add to the system cost. Contract research organizations also need documentation that meets sponsor-specific good laboratory practice requirements. These needs create costs that equipment prices alone do not show. Subscription and per-scan models respond to the constraint, although use remains concentrated among larger organizations that can manage these contracts.

Stringent Preclinical and Animal-Research Regulations

Compliance with EU Directive 2010/63/EU and U.S. animal-research oversight can increase procedural costs and extend study timelines. Smaller organizations can face greater difficulty because they may lack dedicated regulatory support. Repeated anesthesia in longitudinal studies may require additional ethical approval documentation. This requirement can slow the use of designs that otherwise align with the 3Rs principles. International guidance for preclinical radiopharmaceutical studies also identifies inconsistent dosing, acquisition, and analysis protocols as barriers to pooling data across institutions.^{[2]International Atomic Energy Agency, “Guidance for Preclinical Studies With Radiopharmaceuticals,” International Atomic Energy Agency, iaea.org} These gaps can weaken the translational evidence used in biomarker qualification.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Modality: Optical Imaging Leads While Photoacoustic Systems Grow Fastest

Optical imaging systems held 32.47% of modality revenue in 2025, placing them ahead of other modalities in the in-vivo imaging market. Bioluminescence and fluorescence workflows have been deployed widely for many years. Their position rests on lower per-session consumable costs and compatibility with available reporter constructs. They also have simpler operating requirements than nuclear imaging or MRI systems. Nuclear imaging held the second-largest position because PET and SPECT provide quantitative readouts for radiopharmaceutical biodistribution studies. Micro-MRI and micro-ultrasound address more focused needs for soft-tissue contrast and real-time cardiovascular phenotyping.

Photoacoustic imaging systems are forecast to expand at a 10.89% CAGR through 2031, the fastest rate among modality segments. Their capability to provide real-time, non-ionizing, high-resolution vascular and oxygenation information distinguishes them from conventional optical imaging. A 2025 review found that dual photoacoustic and ultrasound systems can provide B-mode, color Doppler, and elastography views for tissue assessment.^{[3] Benoît Arnal et al., “Dual Photoacoustic/Ultrasound Technologies for Preclinical Research: Current Status and Future Trends,”} FUJIFILM VisualSonics launched the Vevo F2 LAZR-X20 platform in June 2025 with a 660-1,320 nm wavelength range for detecting tissue chromophores, including lipids and collagen. Magnetic particle imaging and multimodal cradle-based co-registration systems remain early-stage alternatives. Radioactive tracer workflows can also require radiopharmacy infrastructure, which affects modality selection.

By Reagents: Nuclear Reagents Retain Scale While Optical Probes Expand

Nuclear imaging reagents held 33.58% of reagent revenue in 2025, reflecting the established use of PET and SPECT tracers. The group includes 18F-FDG, 68Ga-labeled peptides, and 99mTc-based compounds used in pharmacokinetic and target-engagement studies. The in-vivo imaging market size for this segment reflects the long-standing role of nuclear methods in quantitative research. MRI, ultrasound, and CT contrast agents support distinct protocols. MRI contrast development is moving toward nanoparticle-based targeted agents that can improve tissue specificity beyond conventional gadolinium formulations. The range of reagent types allows facilities to match agents with modality and biological target.

Optical imaging reagents are forecast to grow at an 11.23% CAGR through 2031. Near-infrared fluorophores, activatable probes, and self-illuminating luciferase systems support greater depth and lower autofluorescence background. These reagents can also enable multiplexed molecular readouts in one imaging session. A 2025 review noted that NIH S10 grants and comparable European mechanisms supported shared optical imaging core facilities at academic medical centers. Multi-spectral unmixing algorithms can separate overlapping fluorescent signals across 4 or more channels. FDA attention to fluorescence-based probes for pharmacodynamic endpoint validation adds a regulatory reason for their use.

By Techniques: Radioisotope Methods Lead While Biomarker-Based Methods Advance

Radioisotopes-based techniques held 42.79% of technique revenue in 2025, the largest share across this segmentation. The in-vivo imaging market continues to rely on established PET and SPECT pharmacokinetic methods. Their position is supported by isotope production and distribution networks in North America and Europe. They also have deep precedent in investigational new drug and new drug application programs. Luminescent protein-based techniques provide a complementary method for tracking cell viability and gene expression over time. These techniques support immuno-oncology and viral-vector biodistribution studies with low background signal.

Biomarker-based techniques are forecast to grow at an 11.94% CAGR through 2031. The FDA and European Medicines Agency's interest in imaging biomarkers supports their use as pharmacodynamic endpoints in investigational new drug submissions. A 2026 study demonstrated integrin αvβ6-targeted PET imaging for mapping epithelial remodeling in preclinical MASH models, with ex vivo human liver biopsy analysis supporting translational relevance. Thermo Fisher Scientific announced a January 2026 collaboration with NVIDIA to advance AI-driven scientific instrumentation. This effort addresses the computational workload in biomarker image analysis. Photoacoustic molecular imaging and Raman-based in-vivo probes remain smaller technique areas with growing academic research interest.

By End User: Hospitals and Clinics Lead While Research Organizations Grow Faster

Hospitals and clinics contributed 42.16% of end-user revenue in 2025, giving them the leading share of the in-vivo imaging market size. Their role combines translational research capacity with clinical-grade diagnostic infrastructure. Imaging centers occupy a middle position, especially in nuclear imaging, where centralized radiopharmacy logistics can support a hub-and-spoke model. The other category includes veterinary research institutions and government defense-related biomedical programs. These users provide steady, though undisclosed, activity. Hospital and clinic demand remains tied to the availability of advanced facilities and trained personnel.

Research organizations are forecast to grow at a 12.63% CAGR through 2031, the fastest rate among end users. This group includes academic medical centers, specialist contract research organizations, and nonprofit research institutes. Pharmaceutical sponsors are outsourcing more early-discovery and investigational new drug-enabling work, encouraging contract research organizations to invest in multimodality suites. Shared imaging core facilities supported by NIH S10 grants and comparable European programs also broaden access to advanced platforms. Research organizations generate many of the imaging biomarker datasets that regulators are beginning to use in qualification frameworks. This position makes them a key source of demand for next-generation reagents and AI analysis tools in the in-vivo imaging industry.

Geography Analysis

North America held 36.16% of the 2026 in-vivo imaging market revenue, supported by the United States’ concentration of publicly funded research centers, pharmaceutical and biotechnology research campuses, and contract research organizations. Canada contributes a growing base in oncology and neuroscience research. Mexico remains an earlier-stage national market. Revenue generation in the region is shifting toward imaging-as-a-service and per-scan models. This shift moves more revenue from equipment sales toward integrated service providers. The FDA Biomarker Qualification Program supports demand for platforms that can produce quantitative data suitable for submissions.

Asia-Pacific is forecast to grow at a 13.51% CAGR from 2026 to 2031, nearly 3 percentage points above the global rate. China is adding preclinical research capacity and is a central demand center in the region. The Chinese government announced funding for 5 new high-resolution micro-CT scanner development programs in 2025, supporting domestic manufacturing capability. Japan’s AMED allocated JPY 8.4 billion, equivalent to USD 56 million, for regenerative medicine imaging programs in 2025. India, South Korea, and Australia also add research infrastructure and academic-industry collaborations. This broad base makes the region’s in-vivo imaging market opportunity wider than China alone.

Europe holds the second position in the in-vivo imaging market, with Germany, the United Kingdom, and France supporting multi-institutional imaging networks. Germany’s Helmholtz Association and United Kingdom Medical Research Council-funded networks help stabilize public-sector procurement. EU Directive 2010/63/EU encourages longitudinal study design while increasing compliance requirements for operators. The Middle East, Africa, and South America remain at earlier stages of adoption. GCC sovereign health investment funds are beginning to support biomedical research infrastructure. Brazil’s regulatory alignment with FDA standards could support São Paulo research clusters as Latin American hubs for imaging-intensive preclinical work. The in-vivo imaging market could benefit if these clusters gain wider access to qualified equipment, radiopharmacy support, and specialized operators.